In conclusion, combining single-cell analysis and genetic murine models, this study shows that CRMO involves multiple layers of inflammatory myeloid cells and provides preclinical evidence supporting that Morrbid could be a therapeutic target for AIDs including chronic osteomyelitis. This evidence concerns the gene MIR4435-2HG and osteomyelitis.